You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDisopyramide
Accession NumberDB00280  (APRD00507)
TypeSmall Molecule
GroupsApproved
DescriptionA class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. [PubChem]
Structure
Thumb
Synonyms
Disopiramida
Disopyramidum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NorpaceCapsule, gelatin coated100 mg/1OralG.D. Searle LLC Division of Pfizer Inc1982-07-20Not applicableUs
NorpaceCapsule, gelatin coated100 mg/1OralCarilion Materials Management1982-07-20Not applicableUs
NorpaceCapsule, gelatin coated150 mg/1OralG.D. Searle LLC Division of Pfizer Inc1982-07-20Not applicableUs
NorpaceCapsule, gelatin coated150 mg/1OralCarilion Materials Management1982-07-20Not applicableUs
NorpaceCapsule, gelatin coated100 mg/1OralG.D. Searle LLC Division of Pfizer Inc1977-09-01Not applicableUs
NorpaceCapsule, gelatin coated150 mg/1OralG.D. Searle LLC Division of Pfizer Inc1977-09-01Not applicableUs
Norpace Cap 100mgCapsule100 mgOralRoberts Pharmaceutical Canada Inc.1994-12-311999-08-11Canada
Norpace Cap 150mgCapsule150 mgOralRoberts Pharmaceutical Canada Inc.1994-12-311999-08-11Canada
Norpace CR 150mgTablet, extended release150 mgOralShire Biochem Inc1994-12-312004-04-30Canada
RythmodanCapsule150 mgOralSanofi Aventis Canada Inc2003-09-152012-05-24Canada
RythmodanCapsule100 mgOralSanofi Aventis Canada Inc2003-09-12Not applicableCanada
Rythmodan Cap 100mgCapsule100 mgOralRoussel Canada Inc.1977-12-311999-08-11Canada
Rythmodan Cap 150mgCapsule150 mgOralRoussel Canada Inc.1978-12-312000-07-28Canada
Rythmodan Capsules 100mgCapsule100 mgOralHoechst Roussel Canada Inc.1997-03-032007-07-31Canada
Rythmodan Capsules 150mgCapsule150 mgOralHoechst Roussel Canada Inc.1996-05-312005-08-01Canada
Rythmodan LA Tab 250mgTablet, extended release250 mgOralRoussel Canada Inc.1984-12-311997-08-05Canada
Rythmodan-LATablet, extended release250 mgOralSanofi Aventis Canada Inc1999-04-302009-10-29Canada
Rythmodan-LA 250mgTablet, extended release250 mgOralHoechst Roussel Canada Inc.1995-12-312001-07-20Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Disopyramide PhosphateCapsule100 mg/1OralCarilion Materials Management1990-09-30Not applicableUs
Disopyramide PhosphateCapsule100 mg/1OralTeva Pharmaceuticals USA Inc1990-09-30Not applicableUs
Disopyramide PhosphateCapsule100 mg/1OralAv Kare, Inc.2014-01-03Not applicableUs
Disopyramide PhosphateCapsule100 mg/1OralMayne Pharma Inc.2016-08-03Not applicableUs
Disopyramide PhosphateCapsule150 mg/1OralTeva Pharmaceuticals USA Inc1990-09-30Not applicableUs
Disopyramide PhosphateCapsule150 mg/1OralAv Kare, Inc.2014-01-03Not applicableUs
Disopyramide PhosphateCapsule150 mg/1OralMayne Pharma Inc.2016-08-03Not applicableUs
Disopyramide PhosphateCapsule100 mg/1OralActavis Pharma, Inc.1985-05-31Not applicableUs
Disopyramide PhosphateCapsule150 mg/1OralCarilion Materials Management1990-09-30Not applicableUs
Disopyramide PhosphateCapsule150 mg/1OralActavis Pharma, Inc.1985-05-31Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DicorantilSanofi
IsorythmSERP
LispineSawai Seiyaku
RitmodanSanofi
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Disopyramide phosphate
22059-60-5
Thumb
  • InChI Key: CGDDQFMPGMYYQP-UHFFFAOYSA-N
  • Monoisotopic Mass: 437.20795814
  • Average Mass: 437.477
DBSALT000899
Categories
UNIIGFO928U8MQ
CAS number3737-09-5
WeightAverage: 339.4745
Monoisotopic: 339.231062565
Chemical FormulaC21H29N3O
InChI KeyUVTNFZQICZKOEM-UHFFFAOYNA-N
InChI
InChI=1/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)
IUPAC Name
4-[bis(propan-2-yl)amino]-2-phenyl-2-(pyridin-2-yl)butanamide
SMILES
CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)C
Pharmacology
IndicationFor the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, ventricular pre-excitation and cardiac dysrhythmias. It is a Class Ia antiarrhythmic drug.
Structured Indications
PharmacodynamicsDisopyramide is an antiarrhythmic drug indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia that are life-threatening. In man, Disopyramide at therapeutic plasma levels shortens the sinus node recovery time, lengthens the effective refractory period of the atrium, and has a minimal effect on the effective refractory period of the AV node. Little effect has been shown on AV-nodal and His-Purkinje conduction times or QRS duration. However, prolongation of conduction in accessory pathways occurs.
Mechanism of actionDisopyramide is a Type 1A antiarrhythmic drug (ie, similar to procainamide and quinidine). It inhibits the fast sodium channels. In animal studies Disopyramide decreases the rate of diastolic depolarization (phase 4) in cells with augmented automaticity, decreases the upstroke velocity (phase 0) and increases the action potential duration of normal cardiac cells, decreases the disparity in refractoriness between infarcted and adjacent normally perfused myocardium, and has no effect on alpha- or beta-adrenergic receptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium channel protein type 5 subunit alphaProteinyes
inhibitor
HumanQ14524 details
Muscarinic acetylcholine receptor M1Proteinunknown
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinunknown
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinunknown
antagonist
HumanP20309 details
Potassium voltage-gated channel subfamily D member 2Proteinunknown
inhibitor
HumanQ9NZV8 details
Potassium voltage-gated channel subfamily D member 3Proteinunknown
inhibitor
HumanQ9UK17 details
Related Articles
AbsorptionNearly complete
Volume of distributionNot Available
Protein binding50%-65%
Metabolism

Hepatic

SubstrateEnzymesProduct
Disopyramide
mono-isopropyl-disopyramideDetails
Route of eliminationIn healthy men, about 50% of a given dose of disopyramide is excreted in the urine as the unchanged drug, about 20% as the mono-N-dealkylated metabolite and 10% as the other metabolites.
Half life6.7 hours (range 4-10 hours)
ClearanceNot Available
ToxicityLD50=580 mg/kg in rats
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Disopyramide Action PathwayDrug actionSMP00325
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Disopyramide.Experimental
AcarboseAcarbose may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
AcebutololDisopyramide may increase the bradycardic activities of Acebutolol.Approved
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Disopyramide.Withdrawn
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Disopyramide.Approved, Vet Approved
AicarAicar may increase the hypoglycemic activities of Disopyramide.Experimental
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
AlogliptinAlogliptin may increase the hypoglycemic activities of Disopyramide.Approved
AlprenololDisopyramide may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Disopyramide.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Disopyramide.Approved
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Disopyramide.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Disopyramide.Approved
AnagrelideAnagrelide may increase the QTc-prolonging activities of Disopyramide.Approved
Aop200704Disopyramide may increase the bradycardic activities of Aop200704.Investigational
ApomorphineApomorphine may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
AprepitantThe serum concentration of Disopyramide can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
ArotinololDisopyramide may increase the bradycardic activities of Arotinolol.Approved
Arsenic trioxideDisopyramide may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherDisopyramide may increase the QTc-prolonging activities of Artemether.Approved
AsenapineDisopyramide may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe metabolism of Disopyramide can be decreased when combined with Atazanavir.Approved, Investigational
AtenololDisopyramide may increase the bradycardic activities of Atenolol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Disopyramide.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Disopyramide.Approved
BalaglitazoneBalaglitazone may increase the hypoglycemic activities of Disopyramide.Investigational
BalsalazideBalsalazide may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
BedaquilineBedaquiline may increase the QTc-prolonging activities of Disopyramide.Approved
BefunololDisopyramide may increase the bradycardic activities of Befunolol.Experimental
BenmoxinBenmoxin may increase the hypoglycemic activities of Disopyramide.Withdrawn
BetaxololDisopyramide may increase the bradycardic activities of Betaxolol.Approved
BevantololDisopyramide may increase the bradycardic activities of Bevantolol.Approved
BexaroteneThe serum concentration of Disopyramide can be decreased when it is combined with Bexarotene.Approved, Investigational
BisoprololDisopyramide may increase the bradycardic activities of Bisoprolol.Approved
BoceprevirThe metabolism of Disopyramide can be decreased when combined with Boceprevir.Approved
BopindololDisopyramide may increase the bradycardic activities of Bopindolol.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
BosentanThe serum concentration of Disopyramide can be decreased when it is combined with Bosentan.Approved, Investigational
BucindololDisopyramide may increase the bradycardic activities of Bucindolol.Investigational
BuforminBuformin may increase the hypoglycemic activities of Disopyramide.Withdrawn
BufuralolDisopyramide may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BupranololDisopyramide may increase the bradycardic activities of Bupranolol.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Disopyramide.Approved
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Disopyramide.Approved
CarbamazepineThe metabolism of Disopyramide can be increased when combined with Carbamazepine.Approved, Investigational
CarbomycinCarbomycin may increase the QTc-prolonging activities of Disopyramide.Vet Approved
CaroxazoneCaroxazone may increase the hypoglycemic activities of Disopyramide.Withdrawn
CarteololDisopyramide may increase the bradycardic activities of Carteolol.Approved
CarvedilolDisopyramide may increase the bradycardic activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may increase the hypoglycemic activities of Disopyramide.Experimental
CeliprololDisopyramide may increase the bradycardic activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Disopyramide can be increased when it is combined with Ceritinib.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
ChlorpropamideDisopyramide may increase the hypoglycemic activities of Chlorpropamide.Approved
CiglitazoneCiglitazone may increase the hypoglycemic activities of Disopyramide.Experimental
CinoxacinCinoxacin may increase the hypoglycemic activities of Disopyramide.Approved, Withdrawn
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
CisaprideDisopyramide may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the QTc-prolonging activities of Disopyramide.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Disopyramide.Approved
ClemastineThe metabolism of Disopyramide can be decreased when combined with Clemastine.Approved
ClomipramineClomipramine may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
ClotrimazoleThe metabolism of Disopyramide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Disopyramide.Approved
CobicistatThe metabolism of Disopyramide can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Disopyramide can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibCrizotinib may increase the QTc-prolonging activities of Disopyramide.Approved
CyclosporineThe metabolism of Disopyramide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Disopyramide can be decreased when it is combined with Dabrafenib.Approved
DapoxetineDapoxetine may increase the hypoglycemic activities of Disopyramide.Investigational
DarunavirThe metabolism of Disopyramide can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Disopyramide can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Disopyramide can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Disopyramide.Approved
DelavirdineThe metabolism of Disopyramide can be decreased when combined with Delavirdine.Approved
DeoxyspergualinDeoxyspergualin may increase the hypoglycemic activities of Disopyramide.Investigational
dersalazinedersalazine may increase the hypoglycemic activities of Disopyramide.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Disopyramide.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Disopyramide.Approved
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Disopyramide.Approved
DexamethasoneThe serum concentration of Disopyramide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Disopyramide.Approved
DihydroergotamineThe metabolism of Disopyramide can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Disopyramide.Illicit
DiltiazemThe metabolism of Disopyramide can be decreased when combined with Diltiazem.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideDofetilide may increase the QTc-prolonging activities of Disopyramide.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Disopyramide.Approved
DomperidoneDisopyramide may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Disopyramide.Approved
DoxycyclineThe metabolism of Disopyramide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneDisopyramide may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
DulaglutideDulaglutide may increase the hypoglycemic activities of Disopyramide.Approved
DuloxetineDuloxetine may increase the hypoglycemic activities of Disopyramide.Approved
EfavirenzThe serum concentration of Disopyramide can be decreased when it is combined with Efavirenz.Approved, Investigational
EliglustatDisopyramide may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Disopyramide.Approved
EnoxacinEnoxacin may increase the hypoglycemic activities of Disopyramide.Approved
EnzalutamideThe serum concentration of Disopyramide can be decreased when it is combined with Enzalutamide.Approved
EribulinEribulin may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
EscitalopramDisopyramide may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Disopyramide can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololDisopyramide may increase the bradycardic activities of Esmolol.Approved
EtoperidoneEtoperidone may increase the hypoglycemic activities of Disopyramide.Approved
EtravirineThe serum concentration of Disopyramide can be decreased when it is combined with Etravirine.Approved
ExenatideExenatide may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Disopyramide.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Disopyramide.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Disopyramide.Approved
FingolimodFingolimod may increase the arrhythmogenic activities of Disopyramide.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Disopyramide.Approved, Withdrawn
FleroxacinFleroxacin may increase the hypoglycemic activities of Disopyramide.Approved
FluconazoleFluconazole may increase the QTc-prolonging activities of Disopyramide.Approved
FlumequineFlumequine may increase the hypoglycemic activities of Disopyramide.Withdrawn
FluoxetineDisopyramide may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Disopyramide.Approved, Illicit
FlupentixolDisopyramide may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluvoxamineThe metabolism of Disopyramide can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
FosamprenavirThe metabolism of Disopyramide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Disopyramide can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Disopyramide.Approved
FosphenytoinDisopyramide may increase the QTc-prolonging activities of Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypoglycemic activities of Disopyramide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Disopyramide can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Disopyramide.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Disopyramide.Approved
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Disopyramide.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
GlibornurideGlibornuride may increase the hypoglycemic activities of Disopyramide.Withdrawn
GliclazideDisopyramide may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideGlimepiride may increase the hypoglycemic activities of Disopyramide.Approved
GlipizideDisopyramide may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneGliquidone may increase the hypoglycemic activities of Disopyramide.Approved
GlyburideDisopyramide may increase the hypoglycemic activities of Glyburide.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Disopyramide.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
GrepafloxacinGrepafloxacin may increase the hypoglycemic activities of Disopyramide.Withdrawn
GusperimusGusperimus may increase the hypoglycemic activities of Disopyramide.Investigational
HaloperidolHaloperidol may increase the QTc-prolonging activities of Disopyramide.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Disopyramide.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Disopyramide.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Disopyramide.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
IbutilideDisopyramide may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Disopyramide can be increased when it is combined with Idelalisib.Approved
IloperidoneDisopyramide may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Disopyramide can be decreased when combined with Imatinib.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Disopyramide.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Disopyramide.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Disopyramide.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Disopyramide.Approved
IndenololDisopyramide may increase the bradycardic activities of Indenolol.Withdrawn
IndinavirThe metabolism of Disopyramide can be decreased when combined with Indinavir.Approved
Insulin AspartDisopyramide may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirDisopyramide may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Disopyramide.Approved
Insulin GlulisineDisopyramide may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanInsulin Human may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Disopyramide.Approved
Insulin PorkInsulin Pork may increase the hypoglycemic activities of Disopyramide.Approved
IproclozideIproclozide may increase the hypoglycemic activities of Disopyramide.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Disopyramide.Withdrawn
IsavuconazoniumThe metabolism of Disopyramide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Disopyramide.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Disopyramide.Approved
ItraconazoleThe serum concentration of Disopyramide can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Disopyramide.Approved
IvacaftorThe serum concentration of Disopyramide can be increased when it is combined with Ivacaftor.Approved
JosamycinJosamycin may increase the QTc-prolonging activities of Disopyramide.Approved
KetoconazoleThe serum concentration of Disopyramide can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoconazoleThe metabolism of Disopyramide can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinKitasamycin may increase the QTc-prolonging activities of Disopyramide.Experimental
LabetalolDisopyramide may increase the bradycardic activities of Labetalol.Approved
LanreotideDisopyramide may increase the hypoglycemic activities of Lanreotide.Approved
LapatinibLapatinib may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Disopyramide.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
LevobunololDisopyramide may increase the bradycardic activities of Levobunolol.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Disopyramide.Approved
LidocaineDisopyramide may increase the arrhythmogenic activities of Lidocaine.Approved, Vet Approved
LinagliptinLinagliptin may increase the hypoglycemic activities of Disopyramide.Approved
LiraglutideLiraglutide may increase the hypoglycemic activities of Disopyramide.Approved
LithiumLithium may increase the QTc-prolonging activities of Disopyramide.Approved
LomefloxacinLomefloxacin may increase the hypoglycemic activities of Disopyramide.Approved
LopinavirDisopyramide may increase the QTc-prolonging activities of Lopinavir.Approved
LovastatinThe metabolism of Disopyramide can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Disopyramide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Disopyramide can be increased when combined with Lumacaftor.Approved
LumefantrineDisopyramide may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneLurasidone may increase the QTc-prolonging activities of Disopyramide.Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Disopyramide.Approved
MebanazineMebanazine may increase the hypoglycemic activities of Disopyramide.Withdrawn
MecaserminDisopyramide may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MefloquineMefloquine may increase the QTc-prolonging activities of Disopyramide.Approved
MesalazineMesalazine may increase the hypoglycemic activities of Disopyramide.Approved
MetforminMetformin may increase the hypoglycemic activities of Disopyramide.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Disopyramide.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Disopyramide.Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Disopyramide.Investigational
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Disopyramide.Approved
MetipranololDisopyramide may increase the bradycardic activities of Metipranolol.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
MetoprololDisopyramide may increase the bradycardic activities of Metoprolol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Disopyramide.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
MiglitolMiglitol may increase the hypoglycemic activities of Disopyramide.Approved
MiglustatMiglustat may increase the hypoglycemic activities of Disopyramide.Approved
MilnacipranMilnacipran may increase the hypoglycemic activities of Disopyramide.Approved
MinaprineMinaprine may increase the hypoglycemic activities of Disopyramide.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Disopyramide.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Disopyramide.Approved
MitiglinideMitiglinide may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
MitotaneThe serum concentration of Disopyramide can be decreased when it is combined with Mitotane.Approved
MoclobemideMoclobemide may increase the hypoglycemic activities of Disopyramide.Approved
ModafinilThe serum concentration of Disopyramide can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Disopyramide.Approved
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
NadololDisopyramide may increase the bradycardic activities of Nadolol.Approved
NafcillinThe serum concentration of Disopyramide can be decreased when it is combined with Nafcillin.Approved
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Disopyramide.Approved
NateglinideDisopyramide may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 4016NCX 4016 may increase the hypoglycemic activities of Disopyramide.Investigational
NefazodoneThe metabolism of Disopyramide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Disopyramide can be decreased when combined with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Disopyramide.Investigational
NetupitantThe serum concentration of Disopyramide can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Disopyramide can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypoglycemic activities of Disopyramide.Withdrawn
NicardipineNicardipine may increase the QTc-prolonging activities of Disopyramide.Approved
NilotinibDisopyramide may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Disopyramide.Investigational
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Disopyramide.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Disopyramide.Approved
OctamoxinOctamoxin may increase the hypoglycemic activities of Disopyramide.Withdrawn
OctreotideOctreotide may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Disopyramide.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
OlaparibThe metabolism of Disopyramide can be decreased when combined with Olaparib.Approved
OleandomycinOleandomycin may increase the QTc-prolonging activities of Disopyramide.Vet Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Disopyramide.Approved
OlsalazineOlsalazine may increase the hypoglycemic activities of Disopyramide.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Disopyramide.Approved
OsimertinibThe serum concentration of Disopyramide can be increased when it is combined with Osimertinib.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
OxprenololDisopyramide may increase the bradycardic activities of Oxprenolol.Approved
OxymetholoneOxymetholone may increase the hypoglycemic activities of Disopyramide.Approved, Illicit
OxytocinOxytocin may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
PalbociclibThe serum concentration of Disopyramide can be increased when it is combined with Palbociclib.Approved
PaliperidoneDisopyramide may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatPanobinostat may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
PargylinePargyline may increase the hypoglycemic activities of Disopyramide.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Disopyramide.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Disopyramide.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Disopyramide.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Disopyramide.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Disopyramide.Approved
PenbutololDisopyramide may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentamidinePentamidine may increase the QTc-prolonging activities of Disopyramide.Approved
PentobarbitalThe metabolism of Disopyramide can be increased when combined with Pentobarbital.Approved, Vet Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Disopyramide.Approved
PhenelzinePhenelzine may increase the hypoglycemic activities of Disopyramide.Approved
PhenforminPhenformin may increase the hypoglycemic activities of Disopyramide.Approved, Withdrawn
PheniprazinePheniprazine may increase the hypoglycemic activities of Disopyramide.Withdrawn
PhenobarbitalThe serum concentration of Disopyramide can be decreased when it is combined with Phenobarbital.Approved
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Disopyramide.Withdrawn
PhenytoinThe serum concentration of Disopyramide can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideDisopyramide may increase the QTc-prolonging activities of Pimozide.Approved
PindololDisopyramide may increase the bradycardic activities of Pindolol.Approved
PioglitazonePioglitazone may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
PirlindolePirlindole may increase the hypoglycemic activities of Disopyramide.Approved
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Disopyramide.Withdrawn
PosaconazoleThe metabolism of Disopyramide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololDisopyramide may increase the bradycardic activities of Practolol.Approved
PramlintidePramlintide may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
PrimaquinePrimaquine may increase the QTc-prolonging activities of Disopyramide.Approved
PrimidoneThe metabolism of Disopyramide can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideDisopyramide may increase the QTc-prolonging activities of Procainamide.Approved
PromazinePromazine may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Disopyramide.Approved
PropafenonePropafenone may increase the arrhythmogenic activities of Disopyramide.Approved
PropofolPropofol may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational, Vet Approved
PropranololDisopyramide may increase the bradycardic activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Disopyramide.Approved
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Disopyramide.Investigational
QuetiapineDisopyramide may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineDisopyramide may increase the QTc-prolonging activities of Quinidine.Approved
QuinineDisopyramide may increase the QTc-prolonging activities of Quinine.Approved
RanolazineRanolazine may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
RasagilineRasagiline may increase the hypoglycemic activities of Disopyramide.Approved
RepaglinideDisopyramide may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RifabutinThe metabolism of Disopyramide can be increased when combined with Rifabutin.Approved
RifampicinThe serum concentration of Disopyramide can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Disopyramide can be increased when combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Disopyramide.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
RitonavirThe metabolism of Disopyramide can be decreased when combined with Ritonavir.Approved, Investigational
RosiglitazoneRosiglitazone may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
RosoxacinRosoxacin may increase the hypoglycemic activities of Disopyramide.Approved
SafrazineSafrazine may increase the hypoglycemic activities of Disopyramide.Withdrawn
SalbutamolSalbutamol may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Disopyramide.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Disopyramide.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Disopyramide.Approved
SelegilineSelegiline may increase the hypoglycemic activities of Disopyramide.Approved, Investigational, Vet Approved
SertralineSertraline may increase the QTc-prolonging activities of Disopyramide.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
SildenafilThe metabolism of Disopyramide can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Disopyramide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Disopyramide can be increased when it is combined with Simeprevir.Approved
SitagliptinSitagliptin may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
SolifenacinSolifenacin may increase the QTc-prolonging activities of Disopyramide.Approved
SolithromycinSolithromycin may increase the QTc-prolonging activities of Disopyramide.Investigational
SorafenibSorafenib may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
SotalolDisopyramide may increase the bradycardic activities of Sotalol.Approved
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Disopyramide.Approved
St. John's WortThe serum concentration of Disopyramide can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololStanozolol may increase the hypoglycemic activities of Disopyramide.Approved, Vet Approved
StiripentolThe serum concentration of Disopyramide can be increased when it is combined with Stiripentol.Approved
SulfadiazineDisopyramide may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Disopyramide.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
SulodexideSulodexide may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Disopyramide.Approved
TelaprevirThe metabolism of Disopyramide can be decreased when combined with Telaprevir.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Disopyramide.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Disopyramide.Approved
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Disopyramide.Withdrawn
TerbutalineTerbutaline may increase the QTc-prolonging activities of Disopyramide.Approved
TestosteroneTestosterone may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
TetrabenazineDisopyramide may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThiazolidinedioneThiazolidinedione may increase the hypoglycemic activities of Disopyramide.Investigational
ThioridazineDisopyramide may increase the QTc-prolonging activities of Thioridazine.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Disopyramide.Approved
TiclopidineThe metabolism of Disopyramide can be decreased when combined with Ticlopidine.Approved
TimololDisopyramide may increase the bradycardic activities of Timolol.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Disopyramide.Approved
TocilizumabThe serum concentration of Disopyramide can be decreased when it is combined with Tocilizumab.Approved
TolazamideDisopyramide may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideDisopyramide may increase the hypoglycemic activities of Tolbutamide.Approved
ToloxatoneToloxatone may increase the hypoglycemic activities of Disopyramide.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
ToremifeneDisopyramide may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Disopyramide.Experimental
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Disopyramide.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Disopyramide.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
TroglitazoneTroglitazone may increase the hypoglycemic activities of Disopyramide.Withdrawn
TroleandomycinTroleandomycin may increase the QTc-prolonging activities of Disopyramide.Approved
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Disopyramide.Approved, Withdrawn
TylosinTylosin may increase the QTc-prolonging activities of Disopyramide.Vet Approved
VandetanibDisopyramide may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Disopyramide.Approved
VemurafenibDisopyramide may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Disopyramide.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Disopyramide.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Disopyramide.Approved
VildagliptinVildagliptin may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
VogliboseVoglibose may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
VoriconazoleThe metabolism of Disopyramide can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
ZimelidineZimelidine may increase the hypoglycemic activities of Disopyramide.Withdrawn
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Disopyramide.Approved
ZuclopenthixolDisopyramide may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.
References
Synthesis Reference

Cusic, J.W. and Sause, H.W.; U.S. Patent 3,225,054; December 21,1965; assigned to G.D. Searle & Co.

US3225054
General ReferencesNot Available
External Links
ATC CodesC01BA03
AHFS Codes
  • 24:04.04.04
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9529
Blood Brain Barrier+0.9508
Caco-2 permeable+0.557
P-glycoprotein substrateSubstrate0.5492
P-glycoprotein inhibitor INon-inhibitor0.8677
P-glycoprotein inhibitor IINon-inhibitor0.8535
Renal organic cation transporterInhibitor0.5702
CYP450 2C9 substrateNon-substrate0.7975
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6906
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8236
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8626
Ames testNon AMES toxic0.8258
CarcinogenicityNon-carcinogens0.8873
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9764 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.996
hERG inhibition (predictor II)Inhibitor0.6168
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Kv pharmaceutical co
  • Gd searle llc
  • Interpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral100 mg/1
CapsuleOral150 mg/1
Capsule, gelatin coatedOral100 mg/1
Capsule, gelatin coatedOral150 mg/1
CapsuleOral150 mg
Tablet, extended releaseOral150 mg
CapsuleOral100 mg
Tablet, extended releaseOral250 mg
Prices
Unit descriptionCostUnit
Norpace CR 150 mg 12 Hour Capsule2.35USD capsule
Norpace cr 150 mg capsule2.26USD capsule
Norpace CR 100 mg 12 Hour Capsule1.98USD capsule
Norpace 150 mg capsule1.94USD capsule
Norpace cr 100 mg capsule1.91USD capsule
Norpace 100 mg capsule1.62USD capsule
Disopyramide Phosphate 150 mg capsule0.96USD capsule
Disopyramide 150 mg capsule0.82USD capsule
Disopyramide Phosphate 100 mg capsule0.72USD capsule
Disopyramide 100 mg capsule0.69USD capsule
Rythmodan 150 mg Capsule0.43USD capsule
Rythmodan 100 mg Capsule0.3USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point94.5-95 °CCusic, J.W. and Sause, H.W.; U.S. Patent 3,225,054; December 21,1965; assigned to G.D. Searle & Co.
water solubility44.9 mg/LNot Available
logP2.58MANNHOLD,R ET AL. (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.0493 mg/mLALOGPS
logP3.21ALOGPS
logP3.47ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)16.19ChemAxon
pKa (Strongest Basic)10.42ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area59.22 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity102.3 m3·mol-1ChemAxon
Polarizability38.82 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pheniramines. These are compounds containing a pheniramine moiety, which is structurally characterized by the presence of a 2-benzylpyridine linked to an dimethyl(propyl)amine to form a dimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine skeleton.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassPheniramines
Direct ParentPheniramines
Alternative Parents
Substituents
  • Pheniramine
  • Phenylacetamide
  • Phenylpropylamine
  • Aralkylamine
  • Fatty acyl
  • Benzenoid
  • Fatty amide
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Primary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function:
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is respon...
Gene Name:
SCN5A
Uniprot ID:
Q14524
Molecular Weight:
226937.475 Da
References
  1. Sugao M, Fujiki A, Nishida K, Sakabe M, Tsuneda T, Iwamoto J, Mizumaki K, Inoue H: Repolarization dynamics in patients with idiopathic ventricular fibrillation: pharmacological therapy with bepridil and disopyramide. J Cardiovasc Pharmacol. 2005 Jun;45(6):545-9. [PubMed:15897781 ]
  2. Fujiki A, Sugao M, Nishida K, Sakabe M, Tsuneda T, Mizumaki K, Inoue H: Repolarization abnormality in idiopathic ventricular fibrillation: assessment using 24-hour QT-RR and QaT-RR relationships. J Cardiovasc Electrophysiol. 2004 Jan;15(1):59-63. [PubMed:15028073 ]
  3. Shimizu W, Antzelevitch C, Suyama K, Kurita T, Taguchi A, Aihara N, Takaki H, Sunagawa K, Kamakura S: Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9. [PubMed:11196553 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Yamamoto N, Ozaki T, Keida Y, Ohtsuka M, Goto T: A comparison of the binding characteristics of class I antiarrhythmic agents for human muscarinic m1-m3 receptors. J Cardiovasc Pharmacol. 1999 Jul;34(1):53-9. [PubMed:10413067 ]
  2. Ishida Y, Mizukami M, Taniguchi T, Satake N, Fujiwara M, Shibata S: Anticholinergic action of disopyramide in intestinal smooth muscle of the guinea pig: inhibition of muscarinic receptors (M1 and M2). Jpn J Pharmacol. 1990 Feb;52(2):363-70. [PubMed:1690310 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Yamamoto N, Ozaki T, Keida Y, Ohtsuka M, Goto T: A comparison of the binding characteristics of class I antiarrhythmic agents for human muscarinic m1-m3 receptors. J Cardiovasc Pharmacol. 1999 Jul;34(1):53-9. [PubMed:10413067 ]
  2. Ishida Y, Mizukami M, Taniguchi T, Satake N, Fujiwara M, Shibata S: Anticholinergic action of disopyramide in intestinal smooth muscle of the guinea pig: inhibition of muscarinic receptors (M1 and M2). Jpn J Pharmacol. 1990 Feb;52(2):363-70. [PubMed:1690310 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Yamamoto N, Ozaki T, Keida Y, Ohtsuka M, Goto T: A comparison of the binding characteristics of class I antiarrhythmic agents for human muscarinic m1-m3 receptors. J Cardiovasc Pharmacol. 1999 Jul;34(1):53-9. [PubMed:10413067 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain. Mediates the major part of the dendritic A-type current I(SA) in brain neurons (By similarity). This current is activated at membrane potentials that are below the threshold for action potentials. It regulates neuronal excitability, prolongs the latency before the firs...
Gene Name:
KCND2
Uniprot ID:
Q9NZV8
Molecular Weight:
70535.825 Da
References
  1. Casis O, Sanchez-Chapula JA: Disopyramide, imipramine, and amitriptyline bind to a common site on the transient outward K+ channel. J Cardiovasc Pharmacol. 1998 Oct;32(4):521-6. [PubMed:9781919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Pore-forming (alpha) subunit of voltage-gated rapidly inactivating A-type potassium channels. May contribute to I(To) current in heart and I(Sa) current in neurons. Channel properties are modulated by interactions with other alpha subunits and with regulatory subunits.
Gene Name:
KCND3
Uniprot ID:
Q9UK17
Molecular Weight:
73450.53 Da
References
  1. Casis O, Sanchez-Chapula JA: Disopyramide, imipramine, and amitriptyline bind to a common site on the transient outward K+ channel. J Cardiovasc Pharmacol. 1998 Oct;32(4):521-6. [PubMed:9781919 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Echizen H, Tanizaki M, Tatsuno J, Chiba K, Berwick T, Tani M, Gonzalez FJ, Ishizaki T: Identification of CYP3A4 as the enzyme involved in the mono-N-dealkylation of disopyramide enantiomers in humans. Drug Metab Dispos. 2000 Aug;28(8):937-44. [PubMed:10901704 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Zhang L, Fitzloff JF, Engel LC, Cook CS: Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide. Xenobiotica. 2001 Feb;31(2):73-83. [PubMed:11407536 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
other/unknown
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Chu JS, Kishion S, Nomura A, Miyazaki K: Serum alpha 1-acid glycoprotein, sialic acid, and protein binding of disopyramide in normal subjects and cardiac patients. Zhongguo Yao Li Xue Bao. 1997 Sep;18(5):408-10. [PubMed:10322928 ]
  2. Hanada K, Ohta T, Hirai M, Arai M, Ogata H: Enantioselective binding of propranolol, disopyramide, and verapamil to human alpha(1)-acid glycoprotein. J Pharm Sci. 2000 Jun;89(6):751-7. [PubMed:10824133 ]
  3. Nakagawa T, Kishino S, Itoh S, Sugawara M, Miyazaki K: Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants. Br J Clin Pharmacol. 2003 Dec;56(6):664-9. [PubMed:14616427 ]
  4. Haughey DB, Steinberg I, Lee MH: Protein binding of disopyramide--displacement by mono-N-dealkyldisopyramide and variation with source of alpha-1-acid glycoprotein. J Pharm Pharmacol. 1985 Apr;37(4):285-8. [PubMed:2860235 ]
  5. Brunner F, Muller WE: Prazosin binding to human alpha 1-acid glycoprotein (orosomucoid), human serum albumin, and human serum. Further characterization of the 'single drug binding site' of orosomucoid. J Pharm Pharmacol. 1985 May;37(5):305-9. [PubMed:2862237 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880 ]
  2. Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. [PubMed:11758759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. [PubMed:11758759 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:11